Clinical Trial Update: Study of TQB2450 Combined With Anlotinib in the Treatment of Mutation Positive Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for TQB2450 in combination with Anlotinib in mutation-positive lung cancer across Phase 1 and Phase 2 stages.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• TQB2450

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Lung Cancer | Phase 1, Phase 2 | Status: UNKNOWN